✦HEALTH · 30% off Purgo Labs✦
Status tracker — last checked 9 October 2026

Retatrutide Phase 3 Results

All four TRIUMPH Phase 3 trials have reported. The numbers, the dates, the conference presentations and the filing plan, each with its source — updated whenever Lilly or the FDA says something new.

Status as of 9 October 2026: not approved, no application filed, BLA planned Q1 2027.

Current Status Summary

TRIUMPH-1 Status
Enrollment Complete
Results expected 2025–2026
TRIUMPH-2 Status
Enrollment Complete
Head-to-head vs tirzepatide
FDA Approval
Not Yet Submitted
Est. NDA submission late 2026

What we know as of 9 October 2026: All four TRIUMPH trials have reported positive topline results, TRIUMPH-1 is published in NEJM, and TRIUMPH-2 was presented in full at EASD on 30 September. Weight loss on 12 mg went up from Phase 2's \u221224.2% at 48 weeks to \u221228.3% at 80 weeks despite the slower Phase 3 titration. Lilly says the data package is complete and plans a Biologics License Application in Q1 2027.

Research use only. Compound Review scores vendors on documentation — laboratory certificates, lot records, pricing and company identity. Nothing on this page is guidance on human or veterinary use, dosing or health outcomes.

Status as of 9 October 2026
Not FDA approved. No application filed yet. Lilly plans to file a Biologics License Application in Q1 2027.
Source: Lilly Q2 2026 results, 5 August 2026 (SEC Form 8-K)
Filing and decision

Biologics License Application (BLA) to the U.S. FDA planned for the first quarter of 2027; the clinical data package is complete for obesity, obstructive sleep apnea and knee osteoarthritis pain.

A Q1 2027 filing puts a standard-review decision in late 2027 or 2028. No date has been set and Lilly has not announced a priority voucher or breakthrough designation.

Phase 3 TRIUMPH results — all four reported
  • TRIUMPH-121 May 2026
    Obesity or overweight, no type 2 diabetes (n = 2,339)
    −28.3% (70.3 lb) at 80 weeks on 12 mg; −25.9% on 9 mg; −19.0% on 4 mg; placebo −2.2%. 45.3% of the 12 mg arm lost ≥30%. Blinded extension to 104 weeks (BMI ≥35): −30.3%.
  • TRIUMPH-223 Jul 2026 (topline)
    Obesity or overweight with type 2 diabetes
    Up to −20.8% (49.6 lb / 22.5 kg) at 80 weeks; A1C reduced by up to 1.6 points.
  • TRIUMPH-323 Jul 2026 (topline)
    BMI ≥35 with established cardiovascular disease
    Up to −22.6% mean weight loss; pre-specified MACE-5 analysis hazard ratio 0.82 vs placebo.
  • TRIUMPH-4Dec 2025
    Obesity with knee osteoarthritis
    −28.7% at 68 weeks; significant improvement in knee pain.
Research-chemical vendors sell retatrutide under names like GLP-3 R, GLP-3 RT or RETA, for laboratory use only. It is not a prescription product and nothing sold that way is Lilly's drug. Our compound page lists which vendors sell it, at what verified price, with which lab-checked certificate. GLP-3 R vendors, prices and certificates · ranked by evidence
Research-grade Retatrutide: who sells it, at what price
every vendor ranked

Retatrutide is not approved for human use and the trial results on this page are Lilly's. The research-grade market sells it under coded names (GLP-3 R, MA-3RT, PG-3RT and similar); the vendors below are scored on documentation, and every price was read from the vendor's own product page on the date shown.

Where to buy Retatrutide
20 partners · prices read from product pages, latest 18 Nov · ranked by rubric, then price
  • 1
    Purgo Labs10/10Lowest per mg
    1 certificate verified at the lab
    10mg vial$59.99
    −30%$41.99
    with code
    Buy
  • 2
    2 certificates verified at the lab
    10mg vial$699.99
    −91%$64.00
    sale $80.00, then code
    Buy
  • 3
    1 certificate verified at the lab
    10mg vial$79.99
    −37%$50.39
    sale $55.99, then code
    Buy
Also stocked by partners we work with. Listed by our choice, outside the ranking above.
  • 2 certificates verified at the labprice read 24 Octfree account needed to see the store
    12mg vial$62.00
    −10%$55.80
    with code
    Buy
  • 2 certificates verified at the labprice read 1 Nov
    10mg vial$74.99
    −10%$67.49
    with code
    Buy
Every order also needs bacteriostatic water — add it to the same cart.All Retatrutide vendors, partners and not
Retatrutide 10mg starts at $34.99 (read 8 Nov 2026). Get an email when a scored vendor goes lower or restocksJoins the Price Report, Mondays and Fridays: every Retatrutide move we read, plus the partner codes now. Unsubscribe in one click. See this week's issue.

Research use only. Prices are list prices read from each vendor's product page on the date shown; code prices are list × (1 − the stated discount), not cart-tested. We earn a commission on partner links; the rubric does not read partner status. How we score.

TRIUMPH Trial Program Details

TRIUMPH-1
Reported — positiveNCT05929066
Population
Adults with obesity or overweight, without type 2 diabetes
Sample Size / Duration
2,339 randomised / 80 weeks (+ blinded extension to 104 weeks for BMI ≥35)
Primary Endpoint
% change in body weight at 80 weeks
Comparator / Reported
Placebo / Topline 21 May 2026; published in NEJM
Significance
−28.3% on 12 mg (70.3 lb), −25.9% on 9 mg, −19.0% on 4 mg vs −2.2% placebo. 45.3% of the 12 mg arm lost ≥30%. Extension: −30.3% at 104 weeks. Discontinuation for adverse events 4.1 / 6.9 / 11.3% vs 4.9%.
TRIUMPH-2
Reported — positive—
Population
Adults with obesity or overweight and type 2 diabetes
Sample Size / Duration
Not disclosed in topline / 80 weeks
Primary Endpoint
% change in body weight and A1C
Comparator / Reported
Placebo / Topline 23 Jul 2026; full data at EASD 30 Sep 2026
Significance
Up to −20.8% (49.6 lb / 22.5 kg) with A1C reduced by up to 1.6 points.
TRIUMPH-3
Reported — positive—
Population
Adults with BMI ≥35 and established cardiovascular disease
Sample Size / Duration
Not disclosed in topline / 80 weeks
Primary Endpoint
% change in body weight; pre-specified MACE-5 safety analysis
Comparator / Reported
Placebo / Topline 23 Jul 2026
Significance
Up to −22.6% mean weight loss; MACE-5 hazard ratio 0.82 vs placebo. A pre-specified safety analysis, not a dedicated outcomes trial.
TRIUMPH-4
Reported — positive—
Population
Adults with obesity and knee osteoarthritis pain
Sample Size / Duration
Not disclosed in topline / 68 weeks
Primary Endpoint
% change in body weight; knee pain
Comparator / Reported
Placebo / Topline Dec 2025
Significance
−28.7% at 68 weeks with significant improvement in knee pain; supports the osteoarthritis-pain indication in the planned filing.

Conference Presentations & Data Updates

ADA 2023

Phase 2 full results presented. 24.2% weight loss at 12 mg confirmed. Lean mass preservation data highlighted.

First comprehensive public presentation of Phase 2 data

EASD 2023

Subgroup analysis presented: retatrutide efficacy in T2D subgroup from Phase 2. HbA1c −2.2% at 12 mg.

Established diabetes efficacy case for TRIUMPH-2

ObesityWeek 2023

Body composition data: ~70% of weight lost was fat mass. Lean mass preservation comparable to tirzepatide.

Addressed key concern about muscle loss with aggressive weight loss

ADA 2024

TRIUMPH enrollment update. Slower titration protocol confirmed for Phase 3. No interim efficacy data released.

Confirmed Phase 3 design changes to address GI tolerability

EASD 2026 (Milan, 30 Sep 2026)

Full TRIUMPH-2 results presented in a dedicated retatrutide symposium: obesity with type 2 diabetes, up to −20.8% at 80 weeks, A1C down up to 1.6 points.

First full presentation of a TRIUMPH trial after the topline releases; the data package Lilly will file in Q1 2027.

EASD 2024

Mechanistic data on glucagon receptor component. Thermogenesis and hepatic lipolysis quantified.

Strengthened scientific differentiation vs dual agonists

What to Expect from Phase 3 Results

Based on the Phase 2 data and Phase 3 design changes, here is what the research community expects from TRIUMPH results:

Weight loss slightly lower than Phase 2

The slower 24-week titration in Phase 3 (vs 12-week in Phase 2) is expected to reduce peak GI adverse events but may also reduce peak weight loss. Analysts project 20–22% average weight loss at the highest dose, vs 24.2% in Phase 2.

Significantly better tolerability

The Phase 2 discontinuation rate of 16% due to adverse events was the primary concern. Phase 3's slower titration is specifically designed to address this. Expect discontinuation rates closer to tirzepatide's 7%.

Strong head-to-head vs tirzepatide in TRIUMPH-2

This is the most anticipated data point. If retatrutide shows superior HbA1c reduction and comparable or better weight loss vs tirzepatide, it will establish a clear clinical differentiation. Even non-inferiority would be commercially significant.

NASH data could be the first approval pathway

Phase 2 showed 82% liver fat reduction — extraordinary for NASH. If TRIUMPH-NASH results are strong, Eli Lilly may pursue NASH as the first FDA indication, similar to how resmetirom (Rezdiffra) received accelerated approval for NASH in 2024.

Source Retatrutide for Research

Third-party tested, batch-verified retatrutide for research purposes.

View Retatrutide at Purgo Labs

Use code HEALTH for 20% off

Frequently Asked Questions

What are the TRIUMPH Phase 3 trial results so far?

All four TRIUMPH trials have reported positive topline results as of 9 October 2026. TRIUMPH-1 (pivotal obesity trial, 2,339 participants, 80 weeks): −28.3% on 12 mg, −25.9% on 9 mg, −19.0% on 4 mg, vs −2.2% on placebo; 45.3% of the 12 mg arm lost at least 30% of body weight. TRIUMPH-2 (obesity with type 2 diabetes): up to −20.8% with A1C down by up to 1.6 points. TRIUMPH-3 (BMI ≥35 with established cardiovascular disease): up to −22.6%, pre-specified MACE-5 hazard ratio 0.82. TRIUMPH-4 (obesity with knee osteoarthritis): −28.7% at 68 weeks.

When were the TRIUMPH results published?

TRIUMPH-4 topline came in December 2025, TRIUMPH-1 on 21 May 2026, and TRIUMPH-2 and TRIUMPH-3 on 23 July 2026. TRIUMPH-1 has been published in the New England Journal of Medicine, and the full TRIUMPH-2 results were presented at the EASD annual meeting in Milan on 30 September 2026.

How does Phase 3 retatrutide differ from Phase 2?

Phase 3 ran longer (80 weeks vs 48) in a far larger population (2,339 in TRIUMPH-1 vs 338 in Phase 2) with a slower dose escalation to limit gastrointestinal events. Weight loss on 12 mg went up, from −24.2% at 48 weeks in Phase 2 to −28.3% at 80 weeks in TRIUMPH-1. Discontinuation for adverse events on 12 mg was 11.3% vs 4.9% on placebo.

Did retatrutide beat tirzepatide in Phase 3?

There is no head-to-head result. TRIUMPH-1's −28.3% at 80 weeks (12 mg) is numerically above tirzepatide's −20.9% at 72 weeks in SURMOUNT-1 (15 mg), but these are different trials with different populations and durations, so the comparison is indicative only.

What is retatrutide's FDA approval status?

Not approved, and no application has been filed as of 9 October 2026. Lilly said on 5 August 2026 that the data package is complete and that it plans to file a Biologics License Application in the first quarter of 2027. That puts a decision in late 2027 or 2028 under a standard review; no priority review has been announced.

What will retatrutide be called when approved?

Lilly has not announced a brand name. The international non-proprietary name is retatrutide. Lilly used different brand names for tirzepatide by indication (Mounjaro for diabetes, Zepbound for obesity), so a similar split is possible. Research-chemical vendors sell a product labelled retatrutide under names like GLP-3 R or GLP-3 RT; that is not Lilly's drug and is not covered by these trial results.